Agentic AI is the difference between AI that answers questions and AI that does the actual work. For RevOps leaders, moving beyond everyday large language models (LLMs) like ChatGPT, Claude, and Perplexity into more of systems/platform AI, a series of agents that work proactively while still responding to ad-hoc requests, is what turns scattered tools into a joined-up revenue engine. Secret Source Specialists are a good example of AI and Humans working in harmony. When deployed within businesses, they instantly add value and dovetail with the in-house sales and marketing teams. This is because the specialists have honed their AI systems/platforms over time, across different environments. So how can you get your AI to work even better?  The three things that make AI work better for you are the power of prompts, quality data, and interconnected systems.

Private equity firms don’t have a marketing problem. They have a value creation execution problem. During the hold period, marketing can’t just generate activity; ultimately, like any other part of the company, it needs to support revenue growth and a stronger exit narrative. Let’s break this issue down. Here are the biggest marketing challenges PE firms need to resolve across portfolio companies.

AI for Sales, Marketing and Service means using artificial intelligence to improve the entire customer journey, from first prospect to loyal customer or partner, in a joined-up, governed way. It's not the same as individual staff using any of the Large Language Models (LLMs, e.g. ChatGPT, Claude) for daily tasks. Done well, it improves customer experience, drives growth and retention, builds efficiency into processes, and empowers people to work alongside AI rather than be replaced by it.

A polished deck can make almost any marketing agency look institutional for 45 minutes.

An AI assessment is a structured audit of where your business stands today and where it could get to, so you invest in AI where it will actually pay off. A Secret Source AI Assessment focuses on Sales, Marketing and Service, meets your key stakeholders, establishes current state versus future state, and produces a prioritised plan to bridge the gap. It is the difference between guessing and knowing.

If you've logged into HubSpot lately and felt a flicker of confusion about Breeze, AI Agents, Assistants, and the credits that power them, you're not alone. It's genuinely hard to know which AI tools to use, when to use them, and how many credits each one quietly eats through in a given month. The good news? Some of HubSpot's most useful AI features don't cost a single credit, which makes them the perfect place to start. This guide answers the questions marketing, sales, and service teams actually ask, so you can spend your credits with confidence (and stop hoarding them out of fear). 

Most value creation plans assume growth has to be bought: more headcount, more spend, more activity. Often it's already sitting inside the business, untapped and uncosted, waiting to be turned into EBITDA.

After investment or acquisition, marketing quickly becomes one of the areas leadership needs to make sense of.

 AI search is reshaping SEO. Here's what AEO (Answer Engine Optimization) means for Marketing Leaders: the three things that change, the numbers behind the awareness gap, and how to audit where you stand today. 

The post test post appeared first on OpenClinica - Your Source for Clinical Trial Technology.

Private equity has become less forgiving. Bain’s 2026 Global Private Equity Report argues that “12 is the new 5”, meaning deals that once needed around 5% annual EBITDA growth to generate target returns may now need closer to 10%-12%.

  We spent 2025 inside hundreds of clinical trials—watching what worked, what didn’t, and why. Across academic labs, emerging biotechs, and established CROs, we saw the same patterns repeat. The teams who finished on time weren’t using more sophisticated systems. They were making smarter choices about workflow, visibility, and support. Here’s what separated the teams […]

The post What 2025 Taught Us About Making Clinical Research Work Better appeared first on OpenClinica - Your Source for Clinical Trial Technology.

Here’s what nobody talks about at industry conferences: many clinical research organizations now use a dozen or more different software tools to run a single trial. EDC platforms. ePRO systems. CTMS. RTSM. eConsent. Safety databases. Lab portals. Each one promising to solve a specific problem. Each one requiring its own login, training, and way of […]

The post The True Cost of Tool Sprawl appeared first on OpenClinica - Your Source for Clinical Trial Technology.

It’s 4 PM on a Friday, and you’re hunting through three different systems trying to answer one question: “Are we on track?” The data exists. The tools exist. But somehow, getting a clear answer feels like solving a puzzle with pieces from different boxes. We already have workflows, data flows, and patient flows — but […]

The post Ease Is How Good Work Happens appeared first on OpenClinica - Your Source for Clinical Trial Technology.

Clinical trial patient recruitment is often challenging, but, in our experience, it doesn’t have to be. The data shows that ~80 percent of clinical trials are “delayed due to recruitment problems and dropout rates are high.” The overwhelming majority of trials (90 percent) have to double their original timeline to meet enrollment goals. More than […]

The post Seven Patient Recruitment Best Practices Used by Leading Research Studies appeared first on OpenClinica - Your Source for Clinical Trial Technology.

Bringing Trial Activities to the Participant Lessons from the RADIAL Proof-of-Concept Trial The move toward more participant-centric clinical research has taken an important step forward. At the Clinical Pharmacology & Therapeutics journal, the first papers from the RADIAL trial, the flagship study of the Trials@Home project have now been published, offering valuable insights into how clinical research […]

The post Bringing Trial Activities to the Participant – Lessons from the RADIAL Proof-of-Concept Trial appeared first on Cambridge Cognition.

Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages The search for reliable, accessible biomarkers for early detection of cognitive decline has taken an important step forward. At AAIC 2025, our team presented data demonstrating that speech and language patterns can serve as valid digital biomarkers for Mild Cognitive Impairment (MCI) and Alzheimer’s disease […]

The post Speech Analysis as an Objective Biomarker in MDD Trials Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages appeared first on Cambridge Cognition.

Summary Clinical research shouldn’t feel like survival mode. The Flow State is about finding the balance between precision and ease — where tools work with you, not against you.  We already have workflows, data flows, and patient flows. But something different happens when everything truly connects — when your day moves smoothly, and the systems […]

The post The Flow State: When Clinical Research Finally Flows appeared first on OpenClinica - Your Source for Clinical Trial Technology.

CTAD | Posters & Presentations Hilton San Diego Bayfront, 1 Park Boulevard – San Diego, CA 92101 | 1-4th December We’re excited to announce we are attending the 18th Clinical Trials on Alzheimer’s Disease (CTAD) This year’s Clinical Trials on Alzheimer’s Disease (CTAD) conference brings together global leaders advancing research and innovation in Alzheimer’s and […]

The post CTAD | Posters & Presentations appeared first on Cambridge Cognition.

DIS | Posters & Presentations Pfizer Innovation Research (PfIRe Lab) 1 Portland St Cambridge, MA 02139 | 5th November 09:00am – 5:30pm PST We’re excited to announce that our team will be attending the 8th Annual Digital Implementation Summit   This year’s Digital Implementation Summit brings together global leaders driving the transformation of clinical development from […]

The post DIS | Posters & Presentations appeared first on Cambridge Cognition.